Jenny Kramer is speaking on the “Enhanced Regulatory Scrutiny of Healthcare Companies” panel at this annual meeting hosted by the Global Investigations Review. This panel will focus on emerging issues in corporate healthcare fraud, including matters involving overseas companies caught in the Department of Justice’s (DOJ) crosshairs.
The panel are expected to discuss:
- FCA violations with a cross-border component (e.g., Ranbaxy’s $500 million settlement with the DOJ)
- Opioid-related enforcement actions and collateral consequences
- Regulatory focus on PE firms and impact on patient care
- Cyberfraud affecting personal health information and decision-making guided by misuse of AI
- Healthcare implications of the DOJ’s M&A safe harbor policy
For more information, click here.